Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Allergy & Immunology
•
Drug Allergy
Do you believe that pretreatment with montelukast or other LTRAs can reduce the risk of urticaria or angioedema with NSAIDS?
Related Questions
Are you using any AI models to de-label penicillin allergy?
Do you utilize any desensitization protocols for delayed hypersensitivity reactions?
Would you consider rechallenging immunotherapy if the first dose was accompanied with an acute infusion reaction with low back pain, shortness of breath and chest pain which resolved with monitoring, and subsequent cardiac workup being negative?
Are drug challenges after serum sickness-like reactions useful in delabeling the allergy?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
For which patients could you consider direct oral amoxicillin challenge as opposed to skin testing for penicillin allergy de-labeling?
Do you recommend desensitization to biologics since this has to occur repeatedly?
Is omalizumab an option for a patient needing a specific antibiotic with an IgE-mediated reaction who continues to have reactions during a desensitization?
Do you perform patch testing with a history of SCAR with the goal of performing a drug challenge?
What medications would you have a patient avoid with an IgE mediated reaction to cyclobenzaprine?
